LLR APC Meeting Minutes – April 2026(394 KB) - LMSG/LLR APC minutes
Date added: 12th May 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| BETULA VERRUCOSA ALLERGEN EXTRACT (Itulazax®) | Orange | Moderate to severe allergic rhinitis/conjunctivitis caused by Birch pollen | |
| Cytisine 1.5mg Tablets (NEW) | Red | For smoking cessation |
Inpatient initiation by hospital stop smoking teams only.
Short-term, 25 day course. Full course to be dispensed at, or, prior to discharge. Patient followed up by the hospital stop smoking team during inpatient stay and after discharge.
In case of treatment failure, the treatment should be discontinued and may be resumed after 2 to 3 months
|
| DEL NIDO CARDIOPLEGIA (NEW) | Red | Cardioplegia in neonatal cardiac surgery | |
| DUPILUMAB (Dupixent®) (NEW) | Red | For Treating Severe Chronic Rhinosinusitis with Nasal polyps |
As per NICE TA1134 Funding: 18th May 2026 |
| DUPILUMAB (Dupixent®) (NEW) | Red | For Maintenance Treatment of Uncontrolled chronic obstructive pulmonary disease with raised Blood Eosinophils |
Funding from: 24th June 2026 |
| NORTRIPTYLINE (NEW) | Green | Use if amitriptyline not tolerated |
Second Choice Not licensed for use in neuropathic pain. Note tablets are usually more cost effective then capsules Exception is 50mg tablets are very expensive and should not be used in LLR. It is much more cost effective to use 2 x 25mg tablets.
|
| ORALTEK (Oraltek®) (NEW) | Red | Sublingual immunotherapy for horse allergy | |
| RUXOLITINIB CREAM (Opzelura®) (NEW) | Red | For Treating Non-Segmental Vitiligo in People 12 years and Over |
Funding from: 15th June 2026 |
| SUCRALFATE ORAL (NEW) | Yellow |
On advice of gastroenterology when other treatments are unsuitable for Treatment of duodenal ulcer, gastric ulcer, chronic gastritis, and the prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients |
|
| SULFASALAZINE | Orange | Rheumatological disease | |
| SYSTANE® ULTRA preservative free eye drops (UPDATED) | Yellow | Ocular lubricant |
Evaporative Dry Eye & Meibomian Gland Dysfunction only |
| TARGETED-RELEASE BUDESONIDE (Kinpeygo®) (UPDATED) | Red | For treating Primary IgA Nephropathy |
In line with NICE TA1128 Funding: 4th May 2026 |
Other Updates on this Website
Recent documents from LLR APC and TAS
Blood Glucose and Ketone Meters, Testing Strips and Lancets Formulary Guideline(295 KB)
Date added: 6th May 2026
Pen Needle Formulary Guideline for Pre-Filled and Reusable Insulin and GLP-1 Receptor Agonist Pens(135 KB)
Date added: 6th May 2026
Sulfasalazine Rheumatology SCA(414 KB)
Date added: 14th Apr 2026
Sulfasalazine Rheumatology Shared Care Request Form National Format(69 KB)
Date added: 14th Apr 2026
Allergen Specific Sublingual Immunotherapy (Acarizax, Grazax and Itulazax) In Paediatrics SCA(778 KB) - Shared care agreement
Date added: 3rd Oct 2024
Allergen Specific Sublingual Immunotherapy (Acarizax, Grazax and Itulazax) in Adults SCA(880 KB) - Shared care agreement
Date added: 6th Sep 2024
Lithium Shared Care Request Form National Format(2 MB) - Shared care agreement
Date added: 29th Dec 2022
Agomelatine Shared Care Request Form National Format(713 KB) - Shared care agreement
Date added: 29th Dec 2022
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more